Grosvenorine (Monk Fruit flavonoid) Attenuates Indomethacin-mediated Gastropathy in Vivo: Role of P53/Bcl-2, Antioxidant, and Inflammatory Mediators

IF 2.7 4区 医学 Q2 PHARMACOLOGY & PHARMACY
Khaled Abdul-Aziz Ahmed, Khalid M. Alqaisi, Ahmed A.j. Jabbar, Parween Abdulsamad Ismail, Noralhuda Ayad Ibrahim, Hanan Ibrahim Althagbi, Rawaz Rizgar Hassan, Muzhda Haydar Saber, Goran Noori Saleh, Musher Ismail saleh, Talal Salem Alqaisi, Ahmed Hameed Al-Dabhawi
{"title":"Grosvenorine (Monk Fruit flavonoid) Attenuates Indomethacin-mediated Gastropathy in Vivo: Role of P53/Bcl-2, Antioxidant, and Inflammatory Mediators","authors":"Khaled Abdul-Aziz Ahmed,&nbsp;Khalid M. Alqaisi,&nbsp;Ahmed A.j. Jabbar,&nbsp;Parween Abdulsamad Ismail,&nbsp;Noralhuda Ayad Ibrahim,&nbsp;Hanan Ibrahim Althagbi,&nbsp;Rawaz Rizgar Hassan,&nbsp;Muzhda Haydar Saber,&nbsp;Goran Noori Saleh,&nbsp;Musher Ismail saleh,&nbsp;Talal Salem Alqaisi,&nbsp;Ahmed Hameed Al-Dabhawi","doi":"10.1007/s12247-025-10115-3","DOIUrl":null,"url":null,"abstract":"<div><p>Natural products have gained renewed interest as therapeutic agents due to their safer effects compared to medicinal therapeutics. As a major flavonoid of <i>Siraitia grosvenorii</i>, Grosvenorine (GVN) has been used for many health purposes. The present study was geared to unveil the marginal safety dosage and gastroprotective potential of GVN in indomethacin-provoked gastropathy in rats. Thirty Sprague-Dawley rats were arbitrarily grouped and pre-treated with either normal saline (groups A and B), 20 mg/kg omeprazole (C), 30 mg/kg GVN (D), or 60 mg/kg GVN (E). Rats in groups B-E received indomethacin (30 mg/kg) and were euthanized for the histopathological and biochemical investigations. Oral delivery of GVN (250 and 500 mg/kg) did not cause any noticeable toxic signs even after a two-week trial. Pretreatment with GVN (30 and 60 mg/kg) significantly inhibited indomethacin-mediated gastric lesion incidence by 69.03% and 74.89%, respectively. The GVN attenuated gastric histological changes (lowered hemorrhagic/lesion areas and gastric tissue disruptions) and strengthened gastric defensive components (mucin/glycoprotein secretion and gastric pH). GVN pretreatment down-regulated apoptotic rates (increased Bcl-2 and lowered P53 proteins) and significantly heightened antioxidant markers (increased glutathione peroxidase, catalase, and superoxide dismutase contents) in gastric tissues exposed to indomethacin-ulceration. The indomethacin-induced lipid peroxidation (MDA) and inflammatory mediators (TNF-α, interleukin-6) were significantly lower in GVN-treated rats, denoting a preserved gastric homeostatic environment. These outcomes demonstrate that GVN exhibits increased gastroprotective potentials via modulation of apoptosis, antioxidant, and inflammatory mediators, making it a viable source for biopharmaceutical/nutraceutical production.</p></div>","PeriodicalId":656,"journal":{"name":"Journal of Pharmaceutical Innovation","volume":"20 5","pages":""},"PeriodicalIF":2.7000,"publicationDate":"2025-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pharmaceutical Innovation","FirstCategoryId":"3","ListUrlMain":"https://link.springer.com/article/10.1007/s12247-025-10115-3","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Natural products have gained renewed interest as therapeutic agents due to their safer effects compared to medicinal therapeutics. As a major flavonoid of Siraitia grosvenorii, Grosvenorine (GVN) has been used for many health purposes. The present study was geared to unveil the marginal safety dosage and gastroprotective potential of GVN in indomethacin-provoked gastropathy in rats. Thirty Sprague-Dawley rats were arbitrarily grouped and pre-treated with either normal saline (groups A and B), 20 mg/kg omeprazole (C), 30 mg/kg GVN (D), or 60 mg/kg GVN (E). Rats in groups B-E received indomethacin (30 mg/kg) and were euthanized for the histopathological and biochemical investigations. Oral delivery of GVN (250 and 500 mg/kg) did not cause any noticeable toxic signs even after a two-week trial. Pretreatment with GVN (30 and 60 mg/kg) significantly inhibited indomethacin-mediated gastric lesion incidence by 69.03% and 74.89%, respectively. The GVN attenuated gastric histological changes (lowered hemorrhagic/lesion areas and gastric tissue disruptions) and strengthened gastric defensive components (mucin/glycoprotein secretion and gastric pH). GVN pretreatment down-regulated apoptotic rates (increased Bcl-2 and lowered P53 proteins) and significantly heightened antioxidant markers (increased glutathione peroxidase, catalase, and superoxide dismutase contents) in gastric tissues exposed to indomethacin-ulceration. The indomethacin-induced lipid peroxidation (MDA) and inflammatory mediators (TNF-α, interleukin-6) were significantly lower in GVN-treated rats, denoting a preserved gastric homeostatic environment. These outcomes demonstrate that GVN exhibits increased gastroprotective potentials via modulation of apoptosis, antioxidant, and inflammatory mediators, making it a viable source for biopharmaceutical/nutraceutical production.

Grosvenorine(罗汉果类黄酮)在体内减轻吲哚美辛介导的胃病:P53/Bcl-2、抗氧化和炎症介质的作用
天然产物作为治疗剂由于其比药物治疗更安全的效果而重新引起人们的兴趣。作为罗汉果的主要类黄酮,罗汉果碱(GVN)已被用于许多保健目的。本研究旨在揭示GVN对吲哚美辛引起的大鼠胃病的边际安全剂量和胃保护潜力。30只Sprague-Dawley大鼠随机分组,分别给予生理盐水(A、B组)、奥美拉唑20 mg/kg (C组)、GVN 30 mg/kg (D组)、GVN 60 mg/kg (E组)预处理。B-E组大鼠给予吲哚美辛(30 mg/kg),安乐死进行组织病理和生化检查。口服GVN(250和500 mg/kg)即使在两周的试验后也没有引起任何明显的毒性迹象。GVN预处理(30和60 mg/kg)可显著抑制吲哚美辛介导的胃病变发生率,分别为69.03%和74.89%。GVN减轻了胃的组织学改变(减少了出血/病变面积和胃组织破坏),增强了胃的防御成分(粘蛋白/糖蛋白分泌和胃pH)。GVN预处理可下调吲哚美辛溃疡胃组织的凋亡率(Bcl-2升高,P53蛋白降低),并显著提高抗氧化标志物(谷胱甘肽过氧化物酶、过氧化氢酶和超氧化物歧化酶含量升高)。吲哚美辛诱导的脂质过氧化(MDA)和炎症介质(TNF-α,白细胞介素-6)在gvn处理大鼠中显著降低,表明胃内稳态环境得到保存。这些结果表明,GVN通过调节细胞凋亡、抗氧化和炎症介质显示出增强的胃保护潜力,使其成为生物制药/营养保健品生产的可行来源。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Pharmaceutical Innovation
Journal of Pharmaceutical Innovation PHARMACOLOGY & PHARMACY-
CiteScore
3.70
自引率
3.80%
发文量
90
审稿时长
>12 weeks
期刊介绍: The Journal of Pharmaceutical Innovation (JPI), is an international, multidisciplinary peer-reviewed scientific journal dedicated to publishing high quality papers emphasizing innovative research and applied technologies within the pharmaceutical and biotechnology industries. JPI''s goal is to be the premier communication vehicle for the critical body of knowledge that is needed for scientific evolution and technical innovation, from R&D to market. Topics will fall under the following categories: Materials science, Product design, Process design, optimization, automation and control, Facilities; Information management, Regulatory policy and strategy, Supply chain developments , Education and professional development, Journal of Pharmaceutical Innovation publishes four issues a year.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信